PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-31.05%
Both companies show declining cash positions (-31.05% vs AXSM's -25.21%). Seth Klarman would examine if this reflects broader market conditions or operational challenges.
No Data
No Data available this quarter, please select a different quarter.
-31.05%
Cash + STI yoy 1.25-1.5x AXSM's -25.21%. Bruce Berkowitz would check if the firm is preparing for expansions or simply hoarding.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.05%
Higher Other Current Assets Growth compared to AXSM's zero value, indicating worse performance.
-31.37%
1.25-1.5x AXSM's -25.98%. Bruce Berkowitz checks if strong current asset growth is used effectively.
76.50%
Below half AXSM's -6.70%. Michael Burry sees potential underinvestment risk unless there's a valid reason (asset-light model).
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
9.08%
Below half of AXSM's -2.47%. Michael Burry might suspect stagnation or lack of resources for expansions.
No Data
No Data available this quarter, please select a different quarter.
-30.47%
1.25-1.5x AXSM's -25.77%. Bruce Berkowitz sees a stronger asset build. Check if it's producing returns.
-21.72%
Less than half of AXSM's 31.25%. David Dodd sees a more disciplined AP approach or lower volume.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-21.72%
Less than half of AXSM's 14.87%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-21.72%
Less than half of AXSM's 4.53%. David Dodd sees far fewer liability expansions relative to competitor.
0.01%
Less than half of AXSM's 2.21%. David Dodd sees fewer share issuances vs. competitor.
-3.53%
Below half AXSM's -9.24%. Michael Burry suspects major net losses or high dividends vs. competitor.
-5.52%
Higher AOCI Growth compared to AXSM's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
-33.13%
Below half AXSM's 100.83%. Michael Burry sees potential underperformance in building shareholder capital.
-30.47%
Below half AXSM's 121.51%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
31.05%
Similar yoy changes to AXSM's 36.92%. Walter Schloss sees parallel net leverage strategies.